Alchemedicine, Inc. / Japan
台灣醫療科技展展位:
Alchemedicine is pre-clinical stage biotech focusing on innovative small molecule drug discovery. In our medicinal chemistry-driven R&D strategy, we are agnostic to disease area and many discovery programs are actively ongoing. We focus on early drug discovery stage, from unique drug design to lead optimization. We identified some clinical candidate compounds, ALK5 inhibitor, CK1 inhibitor, ETA antagonist and ALDH2 activator. We are seeking for partner to establish collaboration or licensing of our compound.
 
成立時間2019
資本額USD 0
員工數0
產品/服務類別
生技製藥
採購與合作需求項目
We need collaboration or drug discovery partners.
供應與銷售項目
ALK5 inhibitor (for Cancers, IPF, FECD)
CK1 inhibitor (for Cancers, ALS, Circadian rhythm disorder)
ETA antagonist (for IgA nephropathy, FSGS, Diabetic nephropathy, etc)
ALDH2 activator (for Fanconi anemia, etc)
最新商機情報
你可能有興趣的產品服務
你可能有興趣的機構/企業
© Institute for Biotechnology and Medicine Industry & Research Center for Biotechnology and Medicine Policy
聯絡我們
Loading...